Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2017—Roche announced the expanded use of the Ventana PD-L1 (SP142) Assay in non-small cell lung cancer and metastatic urothelial carcinoma in CE markets in which the Roche cancer immunotherapy medicine Tecentriq is approved.
September 2017—Roche received FDA approval for the Cobas CMV test for use on its Cobas 6800 and Cobas 8800 Systems. The test is standardized to the 1st WHO International Standard for improving harmonization in cytomegalovirus testing results across hospital institutions.
July 2017—Roche announced the CE-IVD launch of the Cobas Liat PCR System with four assays, including a 20-minute real-time PCR nucleic acid test to detect Clostridium difficile.
June 2017—Roche received 510(k) clearance for its Elecsys Troponin T Gen 5 STAT blood test for patients with a suspected heart attack. With this clearance, according to a company statement, Roche is the first IVD company in the U.S. to provide next-generation troponin testing for patients as an aid in the diagnosis of myocardial infarction, enabling clinicians to more accurately identify patients experiencing a heart attack.
March 2017—Roche announced that its dedicated, high-throughput HbA1c testing solution, the Cobas c 513 analyzer, and HbA1c Gen. 3 assay have received 510(k) clearance from the Food and Drug Administration.
February 2017—Roche launched its Discovery 5-Plex procedure and reagents for immunohistochemistry research applications. This is the first pre-optimized, fully automated multiplex procedure available on the Ventana Discovery Ultra instrument.
October 2016—Roche launched its presence by featuring several next-generation diagnostic testing platforms and a virtual reality experience that was designed to give attendees an “under the hood” look at a lab of the future and a concept Roche calls the “Roche connected lab.”
September 2016—Roche announced the worldwide launch of the Heat-Seq Target Enrichment Systems, which provide rapid and accurate enrichment methods designed to improve the detection of variants in human genetics and cancer research.
May 2016—Roche announced the launch of the Discovery Yellow Kit, an alkaline phosphatase-based detection chemistry for tissue diagnostics that produces a unique, transparent yellow signal that is not washed away during alcohol dehydration.
February 2016—Roche launched the Ventana HE 600 system, its latest fully automated hematoxylin and eosin tissue staining system designed to enhance patient and technician safety and produce exceptional staining quality.
